Glucosio Baxter (Glucose)

Glucosio Baxter is used in clinical settings where rapid glucose supplementation and fluid balance are required.

• Treatment of hypoglycemia when oral intake is not feasible, providing immediate glucose support.
• Component of fluid and electrolyte replacement regimens for postoperative, trauma, or burn patients.
• Source of carbohydrate calories in parenteral nutrition formulations for patients unable to eat.
• Support of energy metabolism during prolonged fasting, critical illness, or major surgery.
• Adjunct in diagnostic procedures that require controlled glucose infusion to maintain stable plasma levels.

Adverse reactions to Glucosio Baxter are generally related to the intravenous administration of a carbohydrate solution.

Common

• Mild hyperglycemia, especially in patients with impaired glucose tolerance.
• Local irritation at the infusion site, such as erythema, pain, or swelling.
• Electrolyte shifts, most commonly a transient decrease in serum potassium.
• Nausea or vomiting associated with rapid infusion rates.
• Transient increase in serum osmolality causing mild thirst.

Serious

• Severe hyperglycemia leading to osmotic diuresis and dehydration.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Fluid overload causing pulmonary edema in patients with compromised cardiac function.
• Metabolic acidosis when large volumes are infused without adequate buffering.
• Severe electrolyte disturbances requiring urgent medical intervention.

When prescribing Glucosio Baxter, clinicians should evaluate patient-specific factors and monitor relevant parameters.

• Assess baseline blood glucose levels before and during infusion to avoid hyper- or hypoglycemia.
• Adjust infusion rate in patients with renal or hepatic impairment due to altered glucose metabolism.
• Use caution in individuals with heart failure or risk of fluid overload; monitor volume status closely.
• Monitor electrolytes, particularly potassium and sodium, throughout therapy.
• Avoid rapid bolus administration unless specifically indicated, to reduce risk of cardiovascular stress.
• Verify compatibility with other intravenous solutions to prevent precipitation or incompatibility reactions.
• Document any signs of allergic response and be prepared to discontinue infusion if severe reactions occur.

Glucosio Baxter may interact with other medications or solutions administered intravenously.

Avoid

• Concurrent use with insulin infusions without dose adjustment, which can cause severe hypoglycemia.
• Co‑administration with potassium‑containing solutions that may precipitate when mixed with high‑glucose concentrations.
• Simultaneous infusion of calcium salts that can form insoluble complexes.

Use with caution

• Concurrent diuretics that alter fluid balance, requiring close monitoring of volume status.
• Vasopressors that affect peripheral perfusion, potentially influencing glucose delivery.
• Anticoagulants, as rapid infusion may affect coagulation parameters in susceptible patients.
• Beta‑blockers, which may mask signs of hypoglycemia during glucose infusion.
• Other hypertonic solutions, which may increase the risk of osmotic shifts if combined.